Since the inflammatory microenvironment in the gastrointestinal tract plays a role in CRC progression via host-immunity interactions48, the upregulation of tumor PD-L2 may be due to adaptive immunity, suggesting that PD-L2 may have prognostic value and can be considered a therapeutic target for immunotherapy in colon carcinoma. The gene discussed is PDCD1LG2; the disease is neoplasm.